#1 Clinical Trials Search in Europe

Phospholipid Fraction, Bovine Lung

Recent clinical trials are investigating the use of Phospholipid Fraction, Bovine Lung, a natural surfactant derived from bovine lungs, in treating various lung conditions. This article explores two significant studies: one focusing on idiopathic pulmonary fibrosis (IPF) in adults, and another examining its use in preterm infants with respiratory distress syndrome. These trials aim to evaluate the effectiveness and safety of this substance in improving lung function and overall patient outcomes.

Table of Contents

What is Phospholipid Fraction from Bovine Lung?

Phospholipid fraction from bovine lung, also known as natural phospholipids or by the brand name Alveofact®, is a medication derived from cow lungs[1]. It belongs to a class of drugs called pulmonary surfactants, which are substances that help keep the air sacs in the lungs open and functioning properly[2].

Medical Conditions Treated

This medication is being studied for its potential to treat various respiratory conditions, including:

  • Idiopathic Pulmonary Fibrosis (IPF): A chronic lung disease that causes scarring (fibrosis) of the lungs, making it difficult to breathe[1].
  • Respiratory Distress Syndrome (RDS) in Preterm Infants: A condition where premature babies’ lungs are not fully developed, making it hard for them to breathe[2].

How It Works

Phospholipid fraction from bovine lung works by:

  • Reducing surface tension in the lungs, which helps keep the tiny air sacs (alveoli) open[1].
  • Improving lung mechanics and breathing function[1].
  • Potentially reducing inflammation and fibrosis in the lungs, especially in conditions like IPF[1].

Administration

The medication is typically administered through:

  • Inhalation: For adults with IPF, the drug is being studied as an inhaled treatment using a special device called a nebulizer[1].
  • Endotracheopulmonary use: For preterm infants, it may be given directly into the lungs through a thin tube[2].

Ongoing Research

Several clinical trials are currently investigating the effectiveness of phospholipid fraction from bovine lung:

  • A study called INSURF-IPF is looking at its effects on lung function in adults with Idiopathic Pulmonary Fibrosis[1].
  • The pro.LISA study is examining its use in preterm infants to prevent and treat Respiratory Distress Syndrome[2].

Potential Benefits

Researchers are hoping to see improvements in:

  • Lung function, particularly Forced Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1)[1][2].
  • Exercise capacity and oxygen levels in the blood[1].
  • Quality of life for patients with respiratory conditions[1].
  • Long-term lung health in preterm infants[2].

Safety and Side Effects

While the medication is still being studied, it’s important to note:

  • Safety is a key focus of the ongoing clinical trials[1].
  • Patients with hypersensitivity to the active substance or any other ingredients should not use this medication[1][2].
  • As with any medication, there may be potential side effects, which will be closely monitored during the studies[1][2].

It’s crucial for patients to discuss any potential treatments with their healthcare providers, as they can provide personalized advice based on individual medical histories and conditions.

Aspect IPF Trial Preterm Infant Trial
Condition Idiopathic Pulmonary Fibrosis Respiratory Distress Syndrome
Patient Group Adults (≥ 18 years) Preterm infants (25-30 weeks gestation)
Administration Inhalation Endotracheopulmonary use
Primary Endpoint Change in Forced Vital Capacity (FVC) FEV1 at 5 years of age
Key Inclusion Criteria FVC > 75% predicted, TLCO > 40% predicted Age ≤ 60 minutes, spontaneous breathing on CPAP
Key Exclusion Criteria Recent exacerbation, concomitant emphysema > 15% Malformations with probable lethal outcome

FAQ

  • What is Phospholipid Fraction, Bovine Lung? Phospholipid Fraction, Bovine Lung is a natural surfactant derived from bovine lungs. It's being studied as a potential treatment for various lung conditions due to its ability to reduce surface tension in the lungs and improve breathing.
  • What conditions are being studied using this substance? Current clinical trials are focusing on idiopathic pulmonary fibrosis (IPF) in adults and respiratory distress syndrome in preterm infants.
  • How is the substance administered in these trials? In the IPF trial, it's administered through inhalation. In the preterm infant trial, it's given through endotracheopulmonary use, which means it's delivered directly into the lungs.
  • What are the main objectives of these trials? The IPF trial aims to evaluate the effect on lung capacity and function in adults. The preterm infant trial seeks to determine if prophylactic use improves lung function at 5 years of age.
  • Are there any known side effects or risks? While the trials are ongoing and full safety profiles are yet to be determined, patients with hypersensitivity to the substance or its ingredients are excluded from participation. The studies also monitor for any adverse events throughout the trial period.

Ongoing Clinical Trials on Phospholipid Fraction, Bovine Lung

  • Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Inhaled Phospholipid Fraction from Bovine Lung for Patients with Idiopathic Pulmonary Fibrosis

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Idiopathic Pulmonary Fibrosis (IPF): A chronic lung disease characterized by scarring (fibrosis) of the lungs, causing breathing difficulties. The term 'idiopathic' means the cause is unknown.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, which is an important measure of lung function.
  • Diffusion Capacity for CO (TLCO): A test that measures how well oxygen moves from the lungs into the blood.
  • Respiratory Distress Syndrome: A breathing disorder that affects newborns, particularly those born prematurely, due to a lack of surfactant in the lungs.
  • Surfactant: A substance that reduces surface tension in the lungs, helping to keep air sacs (alveoli) open and facilitating easier breathing.
  • LISA (Less Invasive Surfactant Administration): A technique for delivering surfactant to preterm infants that is less invasive than traditional methods.
  • FEV1 (Forced Expiratory Volume in 1 second): The amount of air a person can forcefully exhale in one second, which is an important measure of lung function.
  • Endotracheopulmonary: Referring to administration directly into the trachea and lungs.

References

  1. http://clinicaltrials.eu/trial/study-on-inhaled-phospholipid-fraction-from-bovine-lung-for-patients-with-idiopathic-pulmonary-fibrosis/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-phospholipid-fraction-bovine-lung-and-poractant-alfa-in-preterm-infants-with-respiratory-distress-syndrome/